The FAMHP is looking for GPs and gynaecologists willing to take part in a survey on educational material designed to reduce the risk of thromboembolic events associated with combined hormonal contraceptives.

The European Medicines Agency publishes the second European Sales and Use of Antimicrobials for Veterinary Medicine report and launches a new platform to improve monitoring of data on the use of antimicrobials in animals. The report shows a slight increase in antimicrobial sales, an increase of 5 % in 2024 compared to 2023.

From 28 May 2026, it will be mandatory to use the first four modules of the European Database on Medical Devices.

The European press has published information about a Danish sperm donor who carries a rare genetic mutation (TP53). Many European countries have been affected by this. In Belgium, this case has received extensive media coverage since May 2025, and several parliamentary hearings have taken place in which the FAGG responded to questions from federal parliamentarians.

From 11 December 2025, a new Royal Decree will come in force that fundamentally changes the rules on parallel distribution and parallel import of medicinal products for human use in Belgium. The decree simplifies administrative steps and provides more transparency.

Medication errors have occurred with injectable forms of GLP-1 analogues and dual GIP/GLP-1 analogues. Below are a few reminders for a proper use of these medicines.

As of 28 May 2026, it will be mandatory to use the first four modules of the European database on medical devices. This follows a decision published by the European Commission.

From 1 January 2026, the FAMHP will introduce accelerated timelines for the assessment of initial clinical trial applications concerning medicinal products for human use. This measure ensures that clinical research can start faster, to the benefit of the patient, and strengthens Belgium's top position as a centre for clinical trials.